SUBSCRIBE
SUBSCRIBE

Ava Barnes

Pictured: Atopic dermatitis patient scratches thei
FDA
FDA CRL Hurdle for LEO Pharma on Tralokinumab
The U.S. FDA has released a Complete Response Letter (CRL) following its review of LEO Pharma’s tralokinumab. Further data on a device component is the issue brought to light by the recently completed Biologics License Application (BLA) review.
April 30, 2021
 · 
2 min read
 · 
Ava Barnes
Novartis CEO Vas Narasimhan/Courtesy of Novartis
Job Trends
Novartis CEO Says Remote Work Hybrid Should Mean Access to New Talent Pools
Novartis AG Chief Executive Officer Vas Narasimhan believes that the hybrid of remote and on-site office work is the future.
April 28, 2021
 · 
3 min read
 · 
Ava Barnes
A man sits with head in hands/Courtesy of Shutters
Axsome Therapeutics AXS-05 Priority Review by FDA Could Speed Up Help for MDD Patients
In keeping with Axsome’s mission of providing a solution for central nervous system (CNS) disorders that are difficult to treat, AXS-05 was developed to help patients exhibiting treatment-resistant depression (TRD) and major depressive disorder (MDD).
April 26, 2021
 · 
2 min read
 · 
Ava Barnes
Drug Development
When Will Lecanemab be Available to Alzheimer’s Patients?
An optimistic trend reported from the experimental drug lecanemab (BAN2401) clinical trials broaches the question of when the joint asset of Eisai Co., Ltd. and Biogen Inc. will hit the market.
April 20, 2021
 · 
2 min read
 · 
Ava Barnes